In a recent study published in PLoS Computational Biology, researchers used mathematical modelling to evaluate whether prioritizing older individuals for coronavirus disease 2019 (COVID-19) booster vaccinations consistently leads to optimal public health outcomes across diverse socio-economic settings.
In the early stages of the COVID-19 pandemic, non-pharmaceutical interventions (NPIs) were crucial in reducing transmission and protecting healthcare systems.
The introduction of vaccines, such as those from Pfizer-BioNTech, Oxford-AstraZeneca, and Moderna, significantly altered the pandemic’s trajectory by reducing severe cases and relaxing NPIs.
However, immunity from these vaccines wanes over time, necessitating booster vaccinations, especially with emerging variants.
Further research is needed to refine booster vaccination strategies to address varying population structures and socio-economic contexts globally, ensuring the most effective public health outcomes.
About the study
The study extends a previously published age-structured compartmental model of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) transmission and vaccination.
This deterministic model, governed by ordinary differential equations, divides individuals into compartments based on age, current infection status, and immune status before any infection.
The model includes 16 age groups, with individuals classified as Susceptible, Exposed, Infectious (symptomatic or asymptomatic), or Recovered.
To more accurately represent the time spent in the exposed class, the model employs gamma distributions, which provide a realistic representation of epidemiological periods.
The model also tracks immune status, categorizing individuals into groups such as Vaccinated, Boosted, Partially Waned, Fully Waned, and Unvaccinated, reflecting their infection and vaccination history.
The effectiveness of vaccination is incorporated into the model, accounting for reduced risks of infection, symptoms, hospitalization, and death.
Using this model, the study examines the impacts of six different age-based booster vaccination strategies across eight countries. Strategy 1 prioritizes the oldest individuals first, while Strategy 6 explores vaccinating those with the most contacts to provide indirect protection to the elderly.
Strategies 2-5 test variations of these approaches, generally focusing on prioritizing older individuals for booster vaccination. The analysis assumes limited vaccine availability, with a 10% population coverage baseline and a 90% maximum uptake per age group.
Study results
The population’s age structure varies significantly across countries, with high-income countries generally having a larger proportion of older individuals compared to low-income countries.
This demographic difference influences the distribution of booster vaccines under different vaccination strategies. In the UK, for instance, strategies 1-4 that prioritize older individuals for booster vaccination result in a substantial number of individuals aged 50-74 receiving vaccines. However, the oldest individuals (75+) may not be fully covered due to the limited vaccine supply.
On the other hand, Strategies focused on vaccinating younger individuals, particularly those aged 20-49, who typically have more contacts and, therefore, could potentially contribute to indirect protection of older populations.
However, the age distribution of vaccinated individuals under each strategy varies between countries. For example, in Sierra Leone, where the proportion of older individuals is relatively small, Strategies 1-4 effectively vaccinate almost all older individuals, leading to identical outcomes for these strategies.
This contrasts with the situation in the UK, where a larger elderly population means that not all older individuals can be vaccinated under these strategies due to vaccine constraints.
When considering the impact of these strategies on public health outcomes during a wave of infections caused by a novel SARS-CoV-2 variant, the model projections indicated that Strategy 1 consistently resulted in the fewest deaths across all countries analyzed.
This outcome is particularly evident in high-income countries, where a large proportion of older individuals contribute to a higher projected number of deaths if they are not prioritized for booster vaccination.
In contrast, in countries like Sierra Leone, the small number of older individuals allows nearly all of them to receive booster vaccines under Strategy 1, leading to fewer deaths overall.
The analysis also examined the projected Years of Life Lost (YLL), which accounts for the number of deaths and the ages at which they occur.
While it might be expected that vaccinating younger individuals could reduce YLL, the model consistently showed that Strategy 1, which prioritizes the oldest individuals, was optimal in minimizing YLL. This is due to the higher risk of severe outcomes and mortality associated with SARS-CoV-2 infection in older populations.
Sensitivity analyses further supported these findings, showing that Strategy 1 led to fewer deaths and YLL under various assumptions, including different levels of vaccine availability, uptake rates, and timing of booster administration.
Even when the outbreak began 150 days after booster vaccines were administered, resulting in some immunity waning, Strategy 1 remained the most effective approach in reducing deaths and YLL.
Conclusions
To summarize, future SARS-CoV-2 transmission will be influenced by novel variants, booster vaccinations, and immunity dynamics. Unlike the pandemic’s early stages, many individuals globally are now infected or vaccinated, impacting immunity and transmission.
In this evolving scenario, it is essential to reassess the effectiveness of past interventions and explore new strategies.
This study evaluated different age-based booster vaccination strategies and found that prioritizing older individuals consistently leads to better public health outcomes, regardless of varying population structures.
- Bouros I, Hill EM, Keeling MJ, et al. (2024) Prioritizing older individuals for COVID-19 booster vaccination leads to optimal public health outcomes in a range of socio-economic settings. PLoS Comput Biol. doi:https://doi.org/10.1371/journal. pcbi.1012309. https://journals.plos.org/ploscompbiol/article?
News
China closing in but US leads in biotech quality, commercial reach, survey finds
SAN DIEGO, June 22 (Reuters) - China, which now conducts more clinical drug trials, opens new tab than the U.S., still lags in the quality and commercial reach of its biomedical science, according to a recent survey, opens new [...]
New method generates renewable supply of progenitor immune cells
In a paper published in Cell, a USC Stem Cell-led team reports a new way of generating a renewable and expandable supply of the progenitor cells that give rise to macrophages. These immune cells help [...]
Scientists Just Discovered a Cellular Survival System That Was Never Supposed To Exist
A surprising backup pathway allows cells to make a crucial amino acid when their primary machinery fails. For decades, biologists believed cells had only one way to access a molecule they cannot live without. New [...]
Artificial cells gain porous membranes, enabling lab reactions and drug release
Artificial cells created in the laboratory offer a wide range of potential applications. Until now, however, their membranes—unlike those of real cells—have been virtually impermeable. Researchers at the Max Planck Institute for Polymer Research, [...]
Popular Weight-Loss Drugs Like Ozempic Linked to Lower Breast Cancer Risk
Ozempic and similar weight-loss drugs were linked to a striking 30% reduction in breast cancer risk in a study of more than 110,000 women. Popular weight-loss and diabetes medications such as Ozempic, Wegovy, Mounjaro, [...]
Stanford Scientists Discover Explosive New Type of Immune Cell
Scientists studying the remarkable regenerative abilities of planarian flatworms have uncovered a previously unknown type of immune cell with an unusually destructive defense strategy. What if an immune cell could wipe out nearby threats [...]
Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery
Bay Area biotech SonoThera is bubbling to a clinical boil after raising a $125 million series B with the backing of some of the biggest names in pharma. Vida Ventures led the raise, with the venture [...]
Joint initiative of 5 EU countries calls for ‘unified approach’ to pharma framework amid US drug pricing pressure
With drug pricing pressure building from the U.S., a healthcare-focused consortium of five European countries is calling for a “unified approach” to strengthen Europe’s pharmaceutical framework and access to innovative medicines. Belgium, the Netherlands, [...]
Our books now available worldwide!
Online Sellers other than Amazon, Routledge, and IOPP Indigo Global Health Care Equivalency in the Age of Nanotechnology, Nanomedicine and Artifcial Intelligence Global Health Care Equivalency In The Age Of Nanotechnology, Nanomedicine And Artificial [...]
Molecular Manufacturing: The Future of Nanomedicine – New book from NanoappsMedical Inc.
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
NanoMedical Brain/Cloud Interface – Explorations and Implications. A new book from Frank Boehm
New book from Frank Boehm, NanoappsMedical Inc Founder: This book explores the future hypothetical possibility that the cerebral cortex of the human brain might be seamlessly, safely, and securely connected with the Cloud via [...]
New book from Nanoappsmedical Inc. – Global Health Care Equivalency
A new book by Frank Boehm, NanoappsMedical Inc. Founder. This groundbreaking volume explores the vision of a Global Health Care Equivalency (GHCE) system powered by artificial intelligence and quantum computing technologies, operating on secure [...]
UCLA Scientists Uncover a “Hidden Weakness” in Some of the World’s Deadliest Cancers
A new study has uncovered an unexpected vulnerability in some of the deadliest cancers. Researchers at UCLA have identified a previously hidden weakness in some of the most aggressive cancers, pointing to a possible new way [...]
AI-designed universal coronavirus vaccine clears first human trial
Key Takeaways Super-Antigen Technology: Uses AI and machine learning to analyze viral genomes, creating a single vaccine that targets essential features across entire virus families, including coronaviruses and Ebola. Human Trials & Safety: Phase [...]
Researchers Discover a Hidden Vitamin D Problem That Persists Year-Round
A new study suggests that some groups may not experience the expected seasonal boost in vitamin D levels, even during the sunniest months of the year. Many people assume that spending more time outdoors [...]
Researchers Solve the Mystery Behind a Billion-Dollar Dental Implant Disease
Researchers have uncovered why a common and costly dental implant infection often resists antibiotics. Dental implants have helped tens of millions of people regain a full set of stable, functional teeth, something traditional dentures [...]















